Objective: To evaluate the clinical efficacy and safety of Chinese patent medicine Bupi Yichang Pill in the treatment of ulcerative colitis. Method: Use a computer to retrieve English and Chinese database(PubMed, EMBASE, CNKI, VIP, and Wanfang) from the establishment of the database to May 2020. The literature of clinical randomized controlled trials of Chinese patent medicine Bupi Yichang Pill for the treatment of ulcerative colitis were collected. Two researchers independently extracted the data and evaluated the quality of the included studies and meta-analysis was conducted by Using Stata 16.0 software, and the results were graded and evaluated by GRADE. Result: Eight studies with 835 patients were included. The overall analysis showed that Bupi Yichang Pill was more effective than mesalazine sustained-release granules both in mucosal score under colonoscopy (SMD = -0.93, 95％ CI [-1.20, -0.67]) and total efficiency (RR= 1.26, 95％ CI [1.11, 1.43]). Compared with sulfasalazine, Bupi Yichang Pill produced a more significant effect in terms of total efficiency (RR = 1.13, 95％ CI [1.05, 1.21]). In the comparison of total symptom score, Bupi Yichang Pill group was lower than mesalazine sustained-release granules group(SMD = -0.94, 95％ CI [-1.16, -0.72]). The more adverse effect occurred in the mesalazine group when comparing with the Bupi Yichang Pill group (RR = 0.46, 95％ CI [0.16, 1.28]). Conclusion: Bupi Yichang Pill with great safety can effectively improve the clinical effectiveness of ulcerative colitis but the conclusions above are still needed a further study through the higher quality of evidence.